# Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

> **NCT03110484** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 44 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Pemetrexed 500 MG
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT03110484
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2023-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110484, "Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03110484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*